404 related articles for article (PubMed ID: 11356945)
1. Pharmacologic characterization of BMS-191095, a mitochondrial K(ATP) opener with no peripheral vasodilator or cardiac action potential shortening activity.
Grover GJ; D'Alonzo AJ; Garlid KD; Bajgar R; Lodge NJ; Sleph PG; Darbenzio RB; Hess TA; Smith MA; Paucek P; Atwal KS
J Pharmacol Exp Ther; 2001 Jun; 297(3):1184-92. PubMed ID: 11356945
[TBL] [Abstract][Full Text] [Related]
2. Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shortening.
Grover GJ; D'Alonzo AJ; Hess T; Sleph PG; Darbenzio RB
Cardiovasc Res; 1995 Nov; 30(5):731-8. PubMed ID: 8595620
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotective profile of the cardiac-selective ATP-sensitive potassium channel opener BMS-180448.
Grover GJ; McCullough JR; D'Alonzo AJ; Sargent CA; Atwal KS
J Cardiovasc Pharmacol; 1995 Jan; 25(1):40-50. PubMed ID: 7723352
[TBL] [Abstract][Full Text] [Related]
4. In vivo characterization of the mitochondrial selective K(ATP) opener (3R)-trans-4-((4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)dimethyl-2H-1-benzopyran-6-carbonitril monohydrochloride (BMS-191095): cardioprotective, hemodynamic, and electrophysiological effects.
Grover GJ; D'Alonzo AJ; Darbenzio RB; Parham CS; Hess TA; Bathala MS
J Pharmacol Exp Ther; 2002 Oct; 303(1):132-40. PubMed ID: 12235243
[TBL] [Abstract][Full Text] [Related]
5. Cardioselective antiischemic ATP-sensitive potassium channel (K(ATP)) openers. 6. Effect of modifications at C6 of benzopyranyl cyanoguanidines.
Ding CZ; Rovnyak GC; Misra RN; Grover GJ; Miller AV; Ahmed SZ; Kelly Y; Normandin DE; Sleph PG; Atwal KS
J Med Chem; 1999 Sep; 42(18):3711-7. PubMed ID: 10479302
[TBL] [Abstract][Full Text] [Related]
6. Effects of cromakalim and glibenclamide on myocardial high energy phosphates and intracellular pH during ischemia-reperfusion: 31P NMR studies.
Docherty JC; Gunter HE; Kuzio B; Shoemaker L; Yang L; Deslauriers R
J Mol Cell Cardiol; 1997 Jun; 29(6):1665-73. PubMed ID: 9220352
[TBL] [Abstract][Full Text] [Related]
7. Cardioprotective effects of a novel calcium antagonist related to the structure of cromakalim.
Grover GJ; Sleph PG; Dzwonczyk S; McCullough JR
J Pharmacol Exp Ther; 1993 Oct; 267(1):102-7. PubMed ID: 8229736
[TBL] [Abstract][Full Text] [Related]
8. KR-31762, a novel KATP channel opener, exerts cardioprotective effects by opening SarcKATP channels in rat models of ischemia/reperfusion-induced heart injury.
Lee SH; Yang MK; Lim JH; Seo HW; Yi KY; Yoo SE; Lee BH; Won HS; Lee CS; Choi WS; Shin HS
Arch Pharm Res; 2008 Apr; 31(4):482-9. PubMed ID: 18449506
[TBL] [Abstract][Full Text] [Related]
9. BMS-180448, a novel glyburide-reversible cardioprotective agent, enhances postischemic recovery of contractile function in dogs.
Grover GJ; Parham CS; Whigan DB; Mitroka JG
J Pharmacol Exp Ther; 1996 Feb; 276(2):380-7. PubMed ID: 8632300
[TBL] [Abstract][Full Text] [Related]
10. Effect of timing of treatment of the glyburide-reversible cardioprotective activity of BMS-180448.
Gomoll AW; Roth RA; Swillo RE; Baird AJ; Sargent CS; Behling RW; Malone HJ; Grover GJ
J Pharmacol Exp Ther; 1997 Apr; 281(1):24-33. PubMed ID: 9103476
[TBL] [Abstract][Full Text] [Related]
11. The cardioprotective and electrophysiological effects of cromakalim are attenuated by meclofenamate through a cyclooxygenase-independent mechanism.
Grover GJ; D'Alonzo AJ; Sleph PG; Dzwonczyk S; Hess TA; Darbenzio RB
J Pharmacol Exp Ther; 1994 May; 269(2):536-40. PubMed ID: 8182522
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial uncoupling, with low concentration FCCP, induces ROS-dependent cardioprotection independent of KATP channel activation.
Brennan JP; Southworth R; Medina RA; Davidson SM; Duchen MR; Shattock MJ
Cardiovasc Res; 2006 Nov; 72(2):313-21. PubMed ID: 16950237
[TBL] [Abstract][Full Text] [Related]
13. Effects of ATP-sensitive potassium channel activators diazoxide and BMS-191095 on membrane potential and reactive oxygen species production in isolated piglet mitochondria.
Busija DW; Katakam P; Rajapakse NC; Kis B; Grover G; Domoki F; Bari F
Brain Res Bull; 2005 Jul; 66(2):85-90. PubMed ID: 15982523
[TBL] [Abstract][Full Text] [Related]
14. Effect of potassium channel blockade on the anti-ischemic actions of mechanistically diverse agents.
Sargent CA; Smith MA; Dzwonczyk S; Sleph PG; Grover GJ
J Pharmacol Exp Ther; 1991 Oct; 259(1):97-103. PubMed ID: 1920138
[TBL] [Abstract][Full Text] [Related]
15. Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts?
Tosaki A; Szerdahelyi P; Engelman RM; Das DK
J Pharmacol Exp Ther; 1993 Dec; 267(3):1355-62. PubMed ID: 8263798
[TBL] [Abstract][Full Text] [Related]
16. Glyburide-reversible cardioprotective effects of BMS-180448: functional and energetic considerations.
Grover GJ; Sleph PG; Dzwonczyk S; Malone HJ; Behling RW
J Cardiovasc Pharmacol; 1997 Jan; 29(1):28-38. PubMed ID: 9007667
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic profile of the selective mitochondrial-K(ATP) opener BMS-191095 for treatment of acute myocardial ischemia.
Grover GJ; Atwal KS
Cardiovasc Drug Rev; 2002; 20(2):121-36. PubMed ID: 12177690
[TBL] [Abstract][Full Text] [Related]
18. Block of cardiac ATP-sensitive K(+) channels reduces hydroxyl radicals in the rat myocardium.
Obata T; Yamanaka Y
Arch Biochem Biophys; 2000 Jun; 378(2):195-200. PubMed ID: 10860536
[TBL] [Abstract][Full Text] [Related]
19. Protective effects of ATP-sensitive potassium-channel openers in experimental myocardial ischemia.
Grover GJ
J Cardiovasc Pharmacol; 1994; 24 Suppl 4():S18-27. PubMed ID: 7898104
[TBL] [Abstract][Full Text] [Related]
20. Activation of ATP-sensitive K+ channels by cromakalim. Effects on cellular K+ loss and cardiac function in ischemic and reperfused mammalian ventricle.
Venkatesh N; Stuart JS; Lamp ST; Alexander LD; Weiss JN
Circ Res; 1992 Dec; 71(6):1324-33. PubMed ID: 1423930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
